Knight Therapeutics Secures Brazilian Approval for TAVALISSE in Chronic ITP Treatment
Event summary
- Knight Therapeutics' Brazilian affiliate, United Medical Ltda., received ANVISA approval for TAVALISSE (fostamatinib) to treat chronic immune thrombocytopenia (ITP) in adults with insufficient response to prior treatments.
- Approval supported by Phase 3 FIT trials showing 18% of patients on fostamatinib achieved stable platelet response vs. 2% on placebo.
- Knight expects to launch TAVALISSE in Brazil in the second half of 2026, following prior regulatory approvals in Mexico and pending approvals in Colombia, Argentina, and Paraguay.
- TAVALISSE is already marketed in the U.S. as TAVALISSE and in Europe as TAVLESSE for the same indication.
The big picture
Knight Therapeutics' approval of TAVALISSE in Brazil marks another step in its strategy to expand its portfolio of specialized therapies across Latin America. The approval underscores Knight's ability to navigate complex regulatory environments, a critical capability for a company focused on commercializing pharmaceutical products in diverse markets. With fostamatinib already approved in Mexico and pending in other Latin American countries, Knight is positioning itself as a key player in the region's growing biopharmaceutical sector.
What we're watching
- Regulatory Momentum
- Whether Knight can sustain this regulatory approval pace across other Latin American markets, particularly Colombia, Argentina, and Paraguay, where submissions are pending.
- Commercial Execution
- The pace at which Knight can launch and scale TAVALISSE in Brazil, given the country's complex healthcare landscape and competitive ITP treatment landscape.
- Market Differentiation
- How TAVALISSE's unique mechanism of action as a SYK inhibitor will position it against existing ITP therapies like steroids and TPO-RAs in Brazil.
Related topics